P Denig
Overview
Explore the profile of P Denig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Denig P, Edelman M, Taxis K
Ned Tijdschr Geneeskd
. 2021 Feb;
164.
PMID: 33560601
Many healthcare providers agree that reduction or stopping of medication, so-called deprescribing, would be good in vulnerable people with polypharmacy. However, deprescribing is not yet widely conducted. Physicians and pharmacists...
2.
Oktora M, Kerr K, Hak E, Denig P
Diabet Med
. 2020 Sep;
38(2):e14408.
PMID: 32969063
Background: Individualizing goals for people with type 2 diabetes may result in deintensification of medication, but a comprehensive picture of deprescribing practices is lacking. Aims: To conduct a scoping review...
3.
de Vries F, Voorham J, Hak E, Denig P
Int J Clin Pract
. 2016 Apr;
70(6):482-92.
PMID: 27125890
Aims: The aim of this study was to describe and compare treatment modifications and discontinuation, adherence levels and response to treatment in patients with type 2 diabetes initiating on low-dose...
4.
de Vries F, Voorham J, Hak E, Denig P
Curr Med Res Opin
. 2015 Sep;
31(12):2197-206.
PMID: 26359331
Objective: To determine the association between adherence, dose and low-density lipoprotein (LDL) cholesterol response in patients with type 2 diabetes initiating statin treatment. Research Design And Methods: This cohort study...
5.
Wieringa N, Denig P, de Graeff P, Vos R
Neth Heart J
. 2015 Feb;
10(11):441-448.
PMID: 25696043
Objectives/background: The external validity of trial results of new cardiovascular drugs is limited, because the short-term studies are performed with relatively small, highly selected populations. Using qualitative methods, we examined...
6.
de Vries F, Denig P, Vegter S, Bos H, Postma M, Hak E
Curr Med Res Opin
. 2015 Jan;
31(4):595-602.
PMID: 25629791
Objective: To be effective, adherence to statin treatment is essential. We assessed the effect of an apparent first cardiovascular event on statin adherence rates in type 2 diabetes patients. Research...
7.
Martono D, Lub R, Lambers Heerspink H, Hak E, Wilffert B, Denig P
Diabet Med
. 2015 Jan;
32(7):853-64.
PMID: 25582542
Aim: To provide an overview of factors predicting metformin and sulphonylurea treatment response. Background: A large variability between individuals in treatment response to metformin and sulphonylurea derivatives exists. Understanding which...
8.
De Smedt R, Jaarsma T, Ranchor A, van der Meer K, Groenier K, Haaijer-Ruskamp F, et al.
Psychol Health
. 2011 Aug;
27(5):570-87.
PMID: 21827288
This study describes coping strategies that patients with heart failure (HF) use to manage adverse drug events (ADEs). The included coping strategies were social support seeking, information seeking, non-adherence and...
9.
Voorham J, Haaijer-Ruskamp F, Wolffenbuttel B, Stolk R, Denig P
Qual Saf Health Care
. 2010 Apr;
19(5):411-5.
PMID: 20427303
Purpose: Clinical guidelines for cardiometabolic risk management indicate a simple threshold-based strategy for treatment, but physicians and their patients may be reluctant to modify drug treatment after a single elevated...
10.
De Smedt R, Denig P, Haaijer-Ruskamp F, Jaarsma T
Int J Clin Pract
. 2009 Feb;
63(2):233-42.
PMID: 19196362
Background: Data on medication adverse effects (AEs) in chronic heart failure (CHF) are primarily based on results from clinical trials. Little is known about AEs perceived by CHF patients in...